|
BET Bromodomain Inhibitor ZEN-3694 Clinical Trials
8 actively recruiting trials across 6 locations
Also known as: BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694
Irvine, California2 trials
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Phase 1
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Phase 1
Los Angeles, California2 trials
Duarte, California1 trial
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
City of Hope Comprehensive Cancer Center
Phase 2
New Haven, Connecticut1 trial
Augusta, Georgia1 trial
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Augusta University Medical Center
Phase 1
Boston, Massachusetts1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.